Potential cost savings by prevention of adverse drug events with a novel medication review program

Preventable adverse drug events (ADEs) account for appreciable health care costs and patient morbidity and offer an attractive opportunity for health care providers to improve patient care and decrease costs. It has been suggested that pharmacist intervention can prevent admissions and readmissions...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of the American Pharmacists Association 2020-05, Vol.60 (3), p.462-469.e4
Hauptverfasser: Fernández, Elena V., Warriner, Cindy L., David, Tosin, Gordon, Elizabeth, Twigg, Geoffrey, Carroll, Norman V.
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 469.e4
container_issue 3
container_start_page 462
container_title Journal of the American Pharmacists Association
container_volume 60
creator Fernández, Elena V.
Warriner, Cindy L.
David, Tosin
Gordon, Elizabeth
Twigg, Geoffrey
Carroll, Norman V.
description Preventable adverse drug events (ADEs) account for appreciable health care costs and patient morbidity and offer an attractive opportunity for health care providers to improve patient care and decrease costs. It has been suggested that pharmacist intervention can prevent admissions and readmissions due to ADEs. This study assessed the ADEs prevented through a novel medication review program, then estimated the potential cost savings of the prevented ADEs using the literature on cost and prevalence of ADEs that were treated. An innovative pharmacist-run medication review was implemented in 2 pharmacies from November 2016 to July 2017. Patients with diabetes, chronic obstructive pulmonary disease, congestive heart failure, prior myocardial infarction, or stroke were included. Pharmacists recorded information about each potential ADE prevented using a standard tracking form which was de-identified and retrospective cost analysis was conducted. Estimates of ADE cost and prevalence requiring treatment were extracted from the literature and incorporated into a model to estimate the potential savings in prevented ADEs overall and per patient. Because ADE costs vary with severity, ADEs in this study were scored for potential severity. This study included 436 patients with a total of 272 likely and 385 likely or possible ADEs identified. ADEs prevented resulted in an estimated total potential savings of $94,832 (sensitivity analysis [SA]: $2261-$828,921) for likely ADEs and $138,914 (SA: $13,520-$264,308) for likely and possible ADEs. Per patient estimated medication review savings were $218 (SA: $5-$1901) for likely ADEs and $319 (SA: $31-$606) for likely and possible ADEs. The benefit of potential cost savings from providing this medication review was 3.6-5.3 times the pharmacists’ time and salary cost. Pharmacists in this study identified a numerous potential ADEs. By intervening to prevent these ADEs, pharmacists could generate substantial cost savings.
doi_str_mv 10.1016/j.japh.2019.12.004
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2341630743</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1544319119305436</els_id><sourcerecordid>2341630743</sourcerecordid><originalsourceid>FETCH-LOGICAL-c356t-77f7571ce64908aae9913745f3a0a9c27d0c1c7ad09b06a57711c88f4a4d25d73</originalsourceid><addsrcrecordid>eNp9kE1PAyEURYnR2PrxB1wYlm46wsAMQ-LGNH4lTXSha_LKvGlppkOFaRv_vdRal64gvHMveYeQK84yznh5u8gWsJpnOeM643nGmDwiQ15IORKyYMeHO9d8QM5iXDCWq1JXp2SQ3mSlhRyS6ZvvsesdtNT62NMIG9fNIp1-0VXAzW7kO-obCvUGQ0Rah_WM_gwi3bp-ToF2foMtXWLtLPzgKehwmwr8LMDygpw00Ea8_D3Pycfjw_v4eTR5fXoZ309GVhRlP1KqUYXiFkupWQWAWnOhZNEIYKBtrmpmuVVQMz1lJRRKcW6rqpEg67yolTgnN_ve9O_nGmNvli5abFvo0K-jyYXkpWBKioTme9QGH2PAxqyCW0L4MpyZnVuzMDu3ZufW8Nwktyl0_du_nqZl_yIHmQm42wOYtkwGgonWYWeTmIC2N7V3__V_Aynki5o</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2341630743</pqid></control><display><type>article</type><title>Potential cost savings by prevention of adverse drug events with a novel medication review program</title><source>Alma/SFX Local Collection</source><creator>Fernández, Elena V. ; Warriner, Cindy L. ; David, Tosin ; Gordon, Elizabeth ; Twigg, Geoffrey ; Carroll, Norman V.</creator><creatorcontrib>Fernández, Elena V. ; Warriner, Cindy L. ; David, Tosin ; Gordon, Elizabeth ; Twigg, Geoffrey ; Carroll, Norman V.</creatorcontrib><description>Preventable adverse drug events (ADEs) account for appreciable health care costs and patient morbidity and offer an attractive opportunity for health care providers to improve patient care and decrease costs. It has been suggested that pharmacist intervention can prevent admissions and readmissions due to ADEs. This study assessed the ADEs prevented through a novel medication review program, then estimated the potential cost savings of the prevented ADEs using the literature on cost and prevalence of ADEs that were treated. An innovative pharmacist-run medication review was implemented in 2 pharmacies from November 2016 to July 2017. Patients with diabetes, chronic obstructive pulmonary disease, congestive heart failure, prior myocardial infarction, or stroke were included. Pharmacists recorded information about each potential ADE prevented using a standard tracking form which was de-identified and retrospective cost analysis was conducted. Estimates of ADE cost and prevalence requiring treatment were extracted from the literature and incorporated into a model to estimate the potential savings in prevented ADEs overall and per patient. Because ADE costs vary with severity, ADEs in this study were scored for potential severity. This study included 436 patients with a total of 272 likely and 385 likely or possible ADEs identified. ADEs prevented resulted in an estimated total potential savings of $94,832 (sensitivity analysis [SA]: $2261-$828,921) for likely ADEs and $138,914 (SA: $13,520-$264,308) for likely and possible ADEs. Per patient estimated medication review savings were $218 (SA: $5-$1901) for likely ADEs and $319 (SA: $31-$606) for likely and possible ADEs. The benefit of potential cost savings from providing this medication review was 3.6-5.3 times the pharmacists’ time and salary cost. Pharmacists in this study identified a numerous potential ADEs. By intervening to prevent these ADEs, pharmacists could generate substantial cost savings.</description><identifier>ISSN: 1544-3191</identifier><identifier>EISSN: 1544-3450</identifier><identifier>DOI: 10.1016/j.japh.2019.12.004</identifier><identifier>PMID: 31948934</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><ispartof>Journal of the American Pharmacists Association, 2020-05, Vol.60 (3), p.462-469.e4</ispartof><rights>2020 American Pharmacists Association</rights><rights>Copyright © 2019 American Pharmacists Association®. Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c356t-77f7571ce64908aae9913745f3a0a9c27d0c1c7ad09b06a57711c88f4a4d25d73</citedby><cites>FETCH-LOGICAL-c356t-77f7571ce64908aae9913745f3a0a9c27d0c1c7ad09b06a57711c88f4a4d25d73</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31948934$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Fernández, Elena V.</creatorcontrib><creatorcontrib>Warriner, Cindy L.</creatorcontrib><creatorcontrib>David, Tosin</creatorcontrib><creatorcontrib>Gordon, Elizabeth</creatorcontrib><creatorcontrib>Twigg, Geoffrey</creatorcontrib><creatorcontrib>Carroll, Norman V.</creatorcontrib><title>Potential cost savings by prevention of adverse drug events with a novel medication review program</title><title>Journal of the American Pharmacists Association</title><addtitle>J Am Pharm Assoc (2003)</addtitle><description>Preventable adverse drug events (ADEs) account for appreciable health care costs and patient morbidity and offer an attractive opportunity for health care providers to improve patient care and decrease costs. It has been suggested that pharmacist intervention can prevent admissions and readmissions due to ADEs. This study assessed the ADEs prevented through a novel medication review program, then estimated the potential cost savings of the prevented ADEs using the literature on cost and prevalence of ADEs that were treated. An innovative pharmacist-run medication review was implemented in 2 pharmacies from November 2016 to July 2017. Patients with diabetes, chronic obstructive pulmonary disease, congestive heart failure, prior myocardial infarction, or stroke were included. Pharmacists recorded information about each potential ADE prevented using a standard tracking form which was de-identified and retrospective cost analysis was conducted. Estimates of ADE cost and prevalence requiring treatment were extracted from the literature and incorporated into a model to estimate the potential savings in prevented ADEs overall and per patient. Because ADE costs vary with severity, ADEs in this study were scored for potential severity. This study included 436 patients with a total of 272 likely and 385 likely or possible ADEs identified. ADEs prevented resulted in an estimated total potential savings of $94,832 (sensitivity analysis [SA]: $2261-$828,921) for likely ADEs and $138,914 (SA: $13,520-$264,308) for likely and possible ADEs. Per patient estimated medication review savings were $218 (SA: $5-$1901) for likely ADEs and $319 (SA: $31-$606) for likely and possible ADEs. The benefit of potential cost savings from providing this medication review was 3.6-5.3 times the pharmacists’ time and salary cost. Pharmacists in this study identified a numerous potential ADEs. By intervening to prevent these ADEs, pharmacists could generate substantial cost savings.</description><issn>1544-3191</issn><issn>1544-3450</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNp9kE1PAyEURYnR2PrxB1wYlm46wsAMQ-LGNH4lTXSha_LKvGlppkOFaRv_vdRal64gvHMveYeQK84yznh5u8gWsJpnOeM643nGmDwiQ15IORKyYMeHO9d8QM5iXDCWq1JXp2SQ3mSlhRyS6ZvvsesdtNT62NMIG9fNIp1-0VXAzW7kO-obCvUGQ0Rah_WM_gwi3bp-ToF2foMtXWLtLPzgKehwmwr8LMDygpw00Ea8_D3Pycfjw_v4eTR5fXoZ309GVhRlP1KqUYXiFkupWQWAWnOhZNEIYKBtrmpmuVVQMz1lJRRKcW6rqpEg67yolTgnN_ve9O_nGmNvli5abFvo0K-jyYXkpWBKioTme9QGH2PAxqyCW0L4MpyZnVuzMDu3ZufW8Nwktyl0_du_nqZl_yIHmQm42wOYtkwGgonWYWeTmIC2N7V3__V_Aynki5o</recordid><startdate>20200501</startdate><enddate>20200501</enddate><creator>Fernández, Elena V.</creator><creator>Warriner, Cindy L.</creator><creator>David, Tosin</creator><creator>Gordon, Elizabeth</creator><creator>Twigg, Geoffrey</creator><creator>Carroll, Norman V.</creator><general>Elsevier Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20200501</creationdate><title>Potential cost savings by prevention of adverse drug events with a novel medication review program</title><author>Fernández, Elena V. ; Warriner, Cindy L. ; David, Tosin ; Gordon, Elizabeth ; Twigg, Geoffrey ; Carroll, Norman V.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c356t-77f7571ce64908aae9913745f3a0a9c27d0c1c7ad09b06a57711c88f4a4d25d73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fernández, Elena V.</creatorcontrib><creatorcontrib>Warriner, Cindy L.</creatorcontrib><creatorcontrib>David, Tosin</creatorcontrib><creatorcontrib>Gordon, Elizabeth</creatorcontrib><creatorcontrib>Twigg, Geoffrey</creatorcontrib><creatorcontrib>Carroll, Norman V.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of the American Pharmacists Association</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fernández, Elena V.</au><au>Warriner, Cindy L.</au><au>David, Tosin</au><au>Gordon, Elizabeth</au><au>Twigg, Geoffrey</au><au>Carroll, Norman V.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Potential cost savings by prevention of adverse drug events with a novel medication review program</atitle><jtitle>Journal of the American Pharmacists Association</jtitle><addtitle>J Am Pharm Assoc (2003)</addtitle><date>2020-05-01</date><risdate>2020</risdate><volume>60</volume><issue>3</issue><spage>462</spage><epage>469.e4</epage><pages>462-469.e4</pages><issn>1544-3191</issn><eissn>1544-3450</eissn><abstract>Preventable adverse drug events (ADEs) account for appreciable health care costs and patient morbidity and offer an attractive opportunity for health care providers to improve patient care and decrease costs. It has been suggested that pharmacist intervention can prevent admissions and readmissions due to ADEs. This study assessed the ADEs prevented through a novel medication review program, then estimated the potential cost savings of the prevented ADEs using the literature on cost and prevalence of ADEs that were treated. An innovative pharmacist-run medication review was implemented in 2 pharmacies from November 2016 to July 2017. Patients with diabetes, chronic obstructive pulmonary disease, congestive heart failure, prior myocardial infarction, or stroke were included. Pharmacists recorded information about each potential ADE prevented using a standard tracking form which was de-identified and retrospective cost analysis was conducted. Estimates of ADE cost and prevalence requiring treatment were extracted from the literature and incorporated into a model to estimate the potential savings in prevented ADEs overall and per patient. Because ADE costs vary with severity, ADEs in this study were scored for potential severity. This study included 436 patients with a total of 272 likely and 385 likely or possible ADEs identified. ADEs prevented resulted in an estimated total potential savings of $94,832 (sensitivity analysis [SA]: $2261-$828,921) for likely ADEs and $138,914 (SA: $13,520-$264,308) for likely and possible ADEs. Per patient estimated medication review savings were $218 (SA: $5-$1901) for likely ADEs and $319 (SA: $31-$606) for likely and possible ADEs. The benefit of potential cost savings from providing this medication review was 3.6-5.3 times the pharmacists’ time and salary cost. Pharmacists in this study identified a numerous potential ADEs. By intervening to prevent these ADEs, pharmacists could generate substantial cost savings.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>31948934</pmid><doi>10.1016/j.japh.2019.12.004</doi></addata></record>
fulltext fulltext
identifier ISSN: 1544-3191
ispartof Journal of the American Pharmacists Association, 2020-05, Vol.60 (3), p.462-469.e4
issn 1544-3191
1544-3450
language eng
recordid cdi_proquest_miscellaneous_2341630743
source Alma/SFX Local Collection
title Potential cost savings by prevention of adverse drug events with a novel medication review program
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T04%3A31%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Potential%20cost%20savings%20by%20prevention%20of%20adverse%20drug%20events%20with%20a%20novel%20medication%20review%20program&rft.jtitle=Journal%20of%20the%20American%20Pharmacists%20Association&rft.au=Fern%C3%A1ndez,%20Elena%20V.&rft.date=2020-05-01&rft.volume=60&rft.issue=3&rft.spage=462&rft.epage=469.e4&rft.pages=462-469.e4&rft.issn=1544-3191&rft.eissn=1544-3450&rft_id=info:doi/10.1016/j.japh.2019.12.004&rft_dat=%3Cproquest_cross%3E2341630743%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2341630743&rft_id=info:pmid/31948934&rft_els_id=S1544319119305436&rfr_iscdi=true